ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Amlodipine

Also written as “amlodipine”, “Amlodipine 5 mg” and “Amlodipine 10 mg”.

Its studies are mostly in Hypertension · Essential Hypertension · Hyperlipidemias · Kidney Diseases · Hypercholesterolemia, led by 35 companies.

Drug pageAmlodipine: every studyMany companies study it; this page follows only the 170 they lead. All 284 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 25, 2005170 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only570 open or runningphase 4since Aug 25, 2005Aug 25, 2005none ahead
Boehringer Ingelheimits history only220 open or runningphase 4since Oct 14, 2005Oct 14, 2005none ahead
Viatrisits history only130 open or runningphase 4since Aug 31, 2005Aug 31, 2005none ahead
Hanmi Pharmaceuticalits history only110 open or runningphase 3since Jul 14, 2009Jul 14, 2009none ahead
Dr. Reddy's Laboratoriesits history only80 open or runningphase 1since May 26, 2010May 26, 2010none ahead
HK inno.Nits history only50 open or runningphase 3since Feb 16, 2015Feb 10, 2014none ahead
Handokits history only40 open or runningphase 3since Jul 24, 2022Jul 21, 2020none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Feb 9, 2009Feb 9, 2009none ahead
Yuhanits history only41 open or runningphase 4since Sep 4, 2023May 29, 2014none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 3since Jan 8, 2016Feb 14, 2014none ahead

Also a collaborator on its studies: CSPC Pharmaceutical Group and Integrium.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Feb 22, 2011.

  1. Nov 7, 2019Phase 3 study in HypercholesterolemiaYuhan · NCT04158076 · 131 enrolled · Korea, Republic of
  2. Jan 23, 2020Midas Pharma’s first study: phase 1 study in Healthy VolunteersNew to Midas PharmaMidas Pharma · NCT04245046 · 18 enrolled · Jordan
  3. Feb 7, 2020Phase 1 study in Healthy VolunteersMidas Pharma · NCT04262765 · 18 enrolled · Jordan
  4. Jul 21, 2020Handok’s first study: phase 2 study in Essential HypertensionNew to HandokHandok · NCT04488978 · 440 enrolled · Korea, Republic of
  5. Feb 25, 2022Servier’s first study: phase 3 study in Essential HypertensionNew to ServierServier · NCT05288400 · 150 enrolled · Russian Federation
  6. Mar 4, 2022Menarini Group’s first study: phase 4 study in HypertensionNew to Menarini GroupMenarini Group · NCT05279807 · 277 enrolled · Hungary
  7. Jul 24, 2022Phase 3 study in Essential HypertensionHandok · NCT05475665 · 157 enrolled · Korea, Republic of
  8. Aug 22, 2022Phase 4 study in HypertensionMenarini Group · NCT05513937 · 301 enrolled · Bulgaria
  9. Dec 14, 2022Phase 1 study in Healthy VolunteersHandok · NCT05663073 · 46 enrolled · Korea, Republic of
  10. Jan 8, 2023Phase 1 study in Healthy VolunteersHandok · NCT05688085 · 44 enrolled · Korea, Republic of
  11. Sep 4, 2023Phase 4 study in Essential HypertensionYuhan · NCT06041529 · 198 enrolled · South Korea
  12. Oct 15, 2024Hyundai Pharm’s first study: phase 3 study in HypertensionNew to Hyundai PharmHyundai Pharm · NCT06646354 · 125 planned · Korea, Republic of
  13. Apr 27, 2026Celltrion’s first study: phase 3 study in HypertensionNew to CelltrionCelltrion · NCT07564726 · 163 enrolled · South Korea
  14. May 25, 2026Zentiva, k.s.’s first study: phase 3 study in HypertensionNew to Zentiva, k.s.Zentiva, k.s. · NCT07618806 · 344 planned

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in HypertensionZentiva, k.s. · NCT07618806

TargetBeta

“Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
PregabalinruleViatrisphase 4149
GabapentinruleViatrisphase 449
DronedaroneruleSanofiphase 418
NifedipineruleBayerphase 418

Studies

The newest 60 of 170 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07618806Hypertension3Not yet recruitingZentiva, k.s.Dec 31, 2027344
NCT07564726Hypertension · South Korea3CompletedCelltrionFeb 13, 2024163
NCT06646354Hypertension · Korea, Republic of3By invitationHyundai PharmMay 19, 2025125
NCT06041529Essential Hypertension · South Korea4Active, not recruitingYuhanFeb 28, 2026198
NCT05688085Healthy Volunteers · Korea, Republic of1CompletedHandokDec 29, 202244
NCT05663073Healthy Volunteers · Korea, Republic of1CompletedHandokDec 15, 202246
NCT05513937Hypertension · Bulgaria4CompletedMenarini GroupNov 15, 2022301
NCT05475665Essential Hypertension · Korea, Republic of3CompletedHandokMar 30, 2023157
NCT05279807Hypertension · Hungary4CompletedMenarini GroupApr 28, 2022277
NCT05288400Essential Hypertension · Russian Federation3CompletedServierDec 18, 2018150
NCT04488978Essential Hypertension · Korea, Republic of2CompletedHandokNov 9, 2021440
NCT04262765Healthy Volunteers · Jordan1CompletedMidas PharmaMar 26, 201918
NCT04245046Healthy Volunteers · Jordan1CompletedMidas PharmaFeb 18, 201918
NCT04161001Hypertension · Korea, Republic of3UNKNOWNDaewoong PharmaceuticalNov 20, 2021237
NCT04158076Hypercholesterolemia · Korea, Republic of3CompletedYuhanJan 14, 2021131
NCT04322266Healthy · Korea, Republic of1CompletedHanmi PharmaceuticalFeb 13, 201961
NCT04081844Healthy · Korea, Republic of1CompletedHanmi PharmaceuticalJun 28, 201831
NCT03639480Hypertension · Korea, Republic of3UNKNOWNHK inno.NOct 2018180
NCT03566316Hypertension With Hyperlipidemia · Korea, Republic of3CompletedIlDong PharmaceuticalJun 16, 2017134
NCT03461081Hypertension With Hyperlipidemia · Korea, Republic of1CompletedJeil PharmaceuticalJul 12, 201732
NCT03536598Hypertension With Hyperlipidemia3CompletedHK inno.NSep 4, 2017203
NCT03009487Hypertension · Korea, Republic of3CompletedDaewoong PharmaceuticalApr 2018265
NCT02974439Bioequivalence · China1CompletedShanghai Haini PharmaceuticalMar 21, 201760
NCT02969265Hypertension · China3WithdrawnTakedaJul 12, 20180
NCT02944734Essential Hypertension · Korea, Republic of2CompletedShin Poong PharmaceuticalDec 2015392
NCT03210532Hypertension · Korea, Republic of3CompletedDaewon PharmaceuticalSep 2017129
NCT02933658Hypertension1CompletedDaewon PharmaceuticalNov 201571
NCT02899455Hypertension · Korea, Republic of3CompletedHanmi PharmaceuticalJun 2016146
NCT02789475Hypertension · Korea, Republic of1UNKNOWNLotus PharmaceuticalJul 201638
NCT02738632Essential Hypertension · Korea, Republic of3CompletedIlDong PharmaceuticalAug 2016300
NCT02739672Healthy · Korea, Republic of1CompletedIlDong PharmaceuticalApr 6, 201640
NCT02707913Healthy1CompletedBright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical LaboratoriesAug 201617
NCT02651870Hypertension · Korea, Republic of3CompletedChong Kun Dang PharmaceuticalFeb 25, 2016135
NCT02519010Healthy · Egypt1CompletedGenuine Research Center, EgyptMar 201136
NCT02387619Hypertension · Korea, Republic of1CompletedJeil PharmaceuticalMar 201541
NCT02368665Essential Hypertension · Korea, Republic of3CompletedHK inno.NNov 2015180
NCT02368652Essential Hypertension · Korea, Republic of3CompletedHK inno.NNov 2015181
NCT02387554Hypertension · Korea, Republic of1CompletedHanmi PharmaceuticalOct 201433
NCT02295046Healthy · Germany1CompletedDr. Reddy's LaboratoriesOct 201180
NCT02292069Healthy · India1CompletedDr. Reddy's LaboratoriesSep 201190
NCT02261064Healthy1CompletedBoehringer IngelheimFeb 200932
NCT02259829Healthy1CompletedBoehringer IngelheimNov 200784
NCT02259816Healthy1CompletedBoehringer IngelheimAug 200638
NCT02233218Healthy Male Volunteer · Korea, Republic of1CompletedYuhanOct 201460
NCT02243319Healthy · Korea, Republic of1CompletedHanmi PharmaceuticalDec 201424
NCT02193308Healthy1CompletedBoehringer IngelheimNov 200784
NCT02183675Healthy · Japan1CompletedBoehringer IngelheimOct 201436
NCT02172040Hypertension · United Kingdom3CompletedKitov PharmaceuticalsNov 19, 2015152
NCT02206165Essential Hypertension · Korea, Republic of2UNKNOWNChong Kun Dang PharmaceuticalApr 2015456
NCT02152969Hypertension · Korea, Republic of1CompletedYuhanAug 201466
NCT02064556Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalJul 201424
NCT02062645Essential Hypertension · Turkey4CompletedNovartisSep 2015115
NCT02059616Essential Hypertension · Korea, Republic of2UNKNOWNHK inno.NJun 2015384
NCT02058446Essential Hypertension · Taiwan4CompletedTSH BiopharmMar 201436
NCT01911780Hypertension · Japan3CompletedBoehringer IngelheimJan 2015132
NCT01806311Hypertension · Korea, Republic of1CompletedDaewoong PharmaceuticalAug 201336
NCT01506011Fasting · India1CompletedDr. Reddy's LaboratoriesApr 200750
NCT01505998Lecithin Cholesterol Acyltransferase Deficiency · India1CompletedDr. Reddy's LaboratoriesMay 200749
NCT01375322Hypertension · Taiwan4CompletedTSH BiopharmJun 2010226
NCT01302691Hypertension3CompletedMerckApr 1, 2012327

How it is read

Names in the registry

  • “Amlodipine”, 44 entries
  • “amlodipine”, 14 entries
  • “Amlodipine 5 mg”, 9 entries
  • “Amlodipine 10 mg”, 6 entries
  • “valsartan + amlodipine”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.